Hamilton, Bermuda, Dec. 31, 2024 --
Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery
Circular mRNA significantly increasing protein expression vs. linear mRNA
Filed provisional patent application, further expanding IP portfolio
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its nanoparticle-based deliver